Pharmaceuticals

Treadwell Therapeutics Announces The Closing of a $91 Million Series B Financing

NEW YORK and HONG KONG, Nov. 18, 2021 /PRNewswire/ -- Treadwell Therapeutics ("Treadwell"), a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, today announced the closing of an oversubscribed Series B financing, which raised more than$91...

2021-11-18 20:00 3564

ADVANZ PHARMA makes key changes to senior leadership to further accelerate next phase of growth

Dr. Steffen Wagner appointed as new Chief Executive Officer and Andreas Stickler as new Chief Financial Officer LONDON, Nov. 18, 2021 /PRNewswire/ -- ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a specialty pharmaceutical company with a strategic focus on complex medicines in ...

2021-11-18 15:45 5513

China sees huge bounce in pharma rankings ahead of hybrid CPhI & P-MEC China

SHANGHAI, Nov. 18, 2021 /PRNewswire/ -- China's pharma industry has seen a record improvement in its overall score, growth potential and biologics according to new data. TheChina specific findings of the CPhI Annual Report rankings[1] are released ahead of CPhI & P-MEC China - which will take pla...

2021-11-18 15:00 1888

First Subject Dosed in the U.S. Phase I Trial for ASC43F Only Half a Month after IND Approval by the U.S. FDA

SHANGHAI, Nov. 18, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces dosing of the first subject in the U.S. Phase I trial for ASC43F, a first-in-class, fixed-dose combination (FDC) oral tablet with dual targets of thyroid h...

2021-11-18 08:30 3941

Marking One Year Milestone, ADDI Expands Access to Global Data for Alzheimer's Researchers

Organization saw growth in AD Workbench users, data partners, and patient datasets from across the globe, including from low- and middle-income countries  SEATTLE, Nov. 17, 2021 /PRNewswire/ -- Today, the Alzheimer's Disease Data Initiative (ADDI) marked one year of transforming how Alzheimer's d...

2021-11-17 19:00 3725

Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit

BEIJING and DURHAM, N.C., Nov. 17, 2021 /PRNewswire/ -- Brii Biosciences Limited  ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public healt...

2021-11-17 18:52 5116

OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF

SINGAPORE, Nov. 17, 2021 /PRNewswire/ -- OncoOne , a biotechnology company focused on discovering precision medicines for cancer and other indications andGenScript ProBio , a leading CDMO in biologics and gene cell therapy, today announc...

2021-11-17 09:10 3326

Recbio Receives Pharmaceutical Production License from Jiangsu Medical Products Administration for Production of COVID-19 Vaccine

TAIZHOU, China, Nov. 17, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"), a biopharmaceutical company focusing on the research, development and commercialization of innovative vaccines that can address prevalent diseases with significant burdens, recently announced that the c...

2021-11-17 09:00 3359

Kira Pharmaceuticals Appoints Teri Loxam as Chief Operating Officer and Chief Financial Officer

CAMBRIDGE, Mass. and SUZHOU, Jiangsu, China, Nov. 16, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement-targeted therapies to treat immune-mediated diseases, today announced the appointment ofTeri Loxam as Chief Operating Officer (COO...

2021-11-16 19:00 2987

Advanced Sterilization Products' Global Commercial Leader, Nilesh Shah, sets sights on preventing HAIs in Asia

SINGAPORE, Nov. 16, 2021 /PRNewswire/ -- Advanced Sterilization Products' (ASP) recently appointed Vice President, General Manager and Global Commercial Leader, Nilesh Shah looks to strengthen ASP's footing in growing markets to improve healthcare standards by reducing the rate of healthcare-assoc...

2021-11-16 10:05 6688

Baxter Philippines launches My Kidney Journey portal to support patients with Chronic Kidney Disease

MANILA, Philippines, Nov. 16, 2021 /PRNewswire/ -- Baxter Asia Pacific (Baxter), a global leader in dialysis care, announced today the launch ofMy Kidney Journey, a comprehensive online portal to support patients living with Chronic Kidney Disease (CKD) inthe Philippines. Chronic Kidney Disease ...

2021-11-16 10:00 2136

Clinical Studies of PD-L1 Antibody ASC22 for HBV Functional Cure Selected for Inclusion in the "Best of The Liver Meeting's Summary" by AASLD Review Committee

-- Inclusion in the "Best of The Liver Meeting's Summary" is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB -- In patients with the baseline HBsAg level ≤ 500 IU/mL, the Phase IIb study demonstrated sustained HBsAg loss in 19...

2021-11-16 08:35 3691

Nanoform signs GMP agreement and achieves near-term business target

HELSINKI, Nov. 15, 2021 /PRNewswire/ -- Insider information Nanoform Finland Plc November 15, 2021 05:05 p.m. Finnish time / 04:05 p.m. Swedish time Nanoform signs GMP agreement and achieves near-term business target Helsinki, Finland - Nanoform, an innovative nanoparticle medicine enabling ...

2021-11-15 23:17 2296

R&D Milestone: HebaBiz Biotech's application for phase III clinical trial in China for Clevudine (L-FMAU), an anti-hepatitis B virus drug candidate under development has been approved

BEIJING, Nov. 15, 2021 /PRNewswire/ -- HebaBiz Biotech is pleased to announce that inNovember 2021, the Center for Drug Evaluation (CDE) of The National Medical Products Administration (NMPA) ofChina has approved the application for phase III clinical study of Clevudine (L-FMAU), a drug candidate...

2021-11-15 22:47 3527

RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients

- Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care - Top-line results for Part A of the study, designed to evaluate safety and tolerability of RHB-107 and dose sel...

2021-11-15 20:00 4552

Seegene Opens New Subsidiary in Bogotá, Colombia, to Advance Regional COVID-19 Testing

SEOUL, South Korea, Nov. 15, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading biotechnology firm specializing in molecular diagnostics (MDx), has announced the opening of an eighth global subsidiary, strategically located in Bogotá,Colombia. The new entity, known as 'Seegene Colombia S.A....

2021-11-15 19:00 2378

Gannex Announces China NMPA Approved Phase II and III Protocols of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis

SHANGHAI, Nov. 15, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the protocols of Phase II and III clinical trials of ASC42 to treat patients with primary biliary cholangitis (PBC) has been approved by China National ...

2021-11-15 08:30 3728

Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology

SAN FRANCISCO and SUZHOU, China, Nov. 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...

2021-11-15 08:00 3802

Treadwell Therapeutics Announces A Presentation at the 2021 SITC Annual Meeting Featuring a Clinical Trial Update on CFI-402411, a First-in-Class HPK1 inhibitor

NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced a presentation for the Company's CFI-402411 program, an oral, first-in-class inhibitor ofHematopoietic Progenitor Kinase...

2021-11-13 02:56 5457

The New Era Biotechnology deepens cooperation between China and Belarus in the Great Stone China Belarus Industrial Park (CBIP)

MINSK, Belarus, Nov. 12, 2021 /PRNewswire/ -- As an enterprise in CBIP, the New Era Biotechnology Co., Ltd. participated in the fourth edition of the China International Import Expo (CIIE) which opened inShanghai on November 5, 2021.

2021-11-12 09:11 2956
1 ... 176177178179180181182 ... 184

Week's Top Stories